Vaccine Info

Daptacel Vaccine

Authored by
Last reviewed
October 26, 2021

Daptacel Vaccine Description

Daptacel is a combination pediatric vaccine that helps prevent diphtheria, tetanus, and pertussis. It is a five-dose series in infants and children 6 weeks through 6 years of age.

Diphtheria, tetanus, and pertussis are serious diseases caused by bacteria.

Daptacel contains 15 Lf diphtheria toxoid, 5 Lf tetanus toxoid, and acellular pertussis antigens [10 µg detoxified pertussis toxin (PT), 5 µg filamentous hemagglutinin (FHA), 3 µg pertactin, and 5 µg fimbriae types 2 and 3 (FIM)] in each 0.5-mL dose.

Other ingredients per 0.5-mL dose include 1.5 mg aluminum phosphate (0.33 mg of aluminum) as the adjuvant, ≤5 µg residual formaldehyde, <50 nanogram (ng) residual glutaraldehyde and 3.3 mg [0.6% volume per volume (v/v)] 2-phenoxyethanol (not as a preservative).

Daptacel Vaccine Indication

Daptacel is indicated for active immunization against diphtheria, tetanus, and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday). 

Daptacel Vaccine Dosage

Daptacel is administered as an intramuscular injection, as a 5 dose series at 2, 4 and 6 months of age (at intervals of 6-8 weeks), at 15-20 months of age and at 4-6 years of age.

The first dose may be given as early as 6 weeks of age. Four doses of Daptacel constitute a primary immunization course for pertussis.

The fifth dose is a booster for pertussis immunization. Three doses of Daptacel constitute a primary immunization course for diphtheria and tetanus.

The fourth and fifth doses are boosters for diphtheria and tetanus immunization. 

Daptacel Vaccine News

October 18, 2021 - A report published by The Lancet Infectious Diseases discusses the importance of pertussis vaccinations for infants. Infants are very vulnerable to pertussis infections and are at high risk of severe outcomes until they can be vaccinated at 2 months of age.  It is very important for their well-being that they are indirectly protected by those around them.

January 16, 2020 - A report published by Fior Markets, the global diphtheria, pertussis, and tetanus (DTaP) vaccine market is expected to grow from USD 2.97 Billion in 2018 to USD 5.07 Billion by 2026, at a CAGR of 6.91% during the forecast period from 2019-2026. This forecast is based on the growing number of cases of diphtheria, tetanus, and pertussis as well as worldwide governmental vaccine programs.  

Daptacel Vaccine Clinical Trials

Daptacel Vaccine has been involved in hundreds of clinical trials